knowledge -WSS

knowledge

author：Wikipedia 2025-10-02 22:26:53 - browse：9

A sign of Lilly on the top of its biotechnology center — coverage from STAT — Adobe

Eli Lilly reported Thursday that its experimental weekly insulin worked as well as daily basal insulin products in two late-stage studies, paving the way for the drug to compete with a similar weekly insulin developed by Novo Nordisk.

In a 52-week trial of type 2 diabetes patients using insulin for the first time, those on the weekly insulin, called efsitora alfa, had a 1.34% reduction in blood sugar levels, while people on the comparator daily insulin degludec, sold as Tresiba by Novo, had a 1.26% lowering. That resulted in patients having blood sugar levels, known as A1C readings, of 6.87% and 6.95%, respectively.

In a separate 26-week trial of type 2 patients who have been using insulin, those on efsitora and the comparator daily insulin glargine, sold by Lilly as Basaglar and Sanofi as Lantus, both saw A1C reductions of 1.07%, resulting in blood sugar levels of 7.12% and 7.11%, respectively.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New air purifier tech could be key to improving indoor air quality
Next article： Readout Newsletter: Amylyx, Aurinia, and IQVIA

entertainment

WSS

Midwives could help bridge maternal health disparities in the U.S.

Bankrupt Pear's prescription app helped MassHealth save money, data suggests

STAT Boddities: What happens to the brain when we get scared?

Neurocrine congenital adrenal hyperplasia trial succeeds

Medicare to pay more for cardiac rehab in hospital outpatient clinics

Juul documents reveal insider tactics on political lobbying

focus

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

leisure time

Supreme Court strikes down use of affirmative action

Latigo launches with $135 million for Vertex

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Medicare to pay more for cardiac rehab in hospital outpatient clinics

In Memoriam: Notable people who died in 2023

Sick patients collapsed waiting for care at Massachusetts hospital with known safety violations

Hollywood unions extend contract negotiations for actors

The struggle to figure out which patients 'deserve' Wegovy

Hepatitis C has a cure — but many Americans still lack access to it

Eli Lilly CEO gives to Mike Pence presidential super PAC

focus

Why the drug industry's warnings on the IRA's impact fall short

House panel takes first step toward fixing drug shortages

Congress must protect the remaining independent doctors

Report cites 'urgent' need to recruit more diverse clinical trial participants

Artificial intelligence use in health care faces greater scrutiny in 2024

Congress considering partial increase for doctor pay in Medicare

Wikipedia

entertainment

hotspot

focus